Fengping received his PhD from the Pennsylvania State University where he studied risk genes related to schizophrenia and autism spectrum disorders. He joined the Milbrandt and Mitra labs with interests of applying a series of functional genomics tools to understand neurodevelopmental diseases. Combining CRISPR/Cas9-mediated gene regulation with next-generation sequencing, he aims to discover underlying molecular mechanisms of neurological diseases. His work will focus on understanding how risk genes contribute to intellectual and developmental disabilities using induced pluripotent stem cells (iPSCs).